reports
- Erik Molenaar
Abbvie, attractive valuation but some side notes.
Abbvie with sector report. The company has been compared with 16 other pharmaceutial and biotechnoly companies. Helpfull with easy and appropriate fund allocation guidelines within the sector. Abbvie its high amount of debt catches the eye and is somewhat special.
- Erik Molenaar
Abbvie, aantrekkelijk geprijsd maar een aantal kanttekeningen.
Abbvie en sectorrapport. Het aandeel wordt vergeleken met 16 andere sector genoten. Het rapport bevat tegelijkertijd een sector rapport waardoor de toewijzing van middelen binnen de sector farmacie en biotechnologie aan individuele aandelen zowel ondersteunend als gemakkelijk wordt.
- Erik Molenaar
Johnson & Johnson, its place in the healthcare and biotechnology secto...
Includes full sector report with 17 healthcare and biotechnology companies, where Johnson & Johnson is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Biogen, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Merck, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology s...
- Erik Molenaar
Biogen, its place in the healthcare and biotechnology sector and full ...
Includes full sector report with 17 healthcare and biotechnology companies, where Biogen is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Merck, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology s...
- Erik Molenaar
Merck, its place in the healthcare and biotechnology sector and full s...
Includes full sector report with 17 healthcare and biotechnology companies, where Merck is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Biogen, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology s...
- Erik Molenaar
Amgen, its place in the healthcare and biotechnology sector and full s...
Includes full sector report with 17 healthcare and biotechnology companies, where Amgen is analysed in perspective of Abbott Laboratories, Abbvie, AstraZeneca plc, Bayer AG, Biogen, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Merck, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healtcare and biotechnologogy sector an...
- Erik Molenaar
Solid income perspective makes valuation attractive
Former state owned ASR is listed on Euronext Amsterdam since June 10th 2016. The Dutch state has sold its entire position in ASR quite recently. This report discusses the stand alone investment value of ASR and its relative atrractiveness in the sector, in comparison with six other insurance companies in Central Europe, AEGON, Ageas, Allianz, AXA, CNP Assurances and Nationale Nederlanden.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.